|
Market Cap | 1.05M | EPS (ttm) | -76.57 |
P/E | - | EPS this Y | 84.36% |
Forward P/E | - | EPS next Y | 9.02% |
PEG | - | EPS past 5Y | 42.24% |
P/S | - | EPS next 5Y | - |
P/B | 0.36 | EPS Q/Q | -120.70% |
Dividend | - | Sales Q/Q | - |
Insider Own | 4.76% | Inst Own | 9.68% |
Insider Trans | 0.00% | Inst Trans | -69.46% |
Short Float | 3.86% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 300.00 |
Avg Volume | 98.03K | 52W Range | 1.46 - 55.12 |
|
|
|
Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Walsh Deina H | Chief Financial Officer | Sep 13 '23 | Buy | 0.64 | 8,000 | 5,120 | 15,000 | Sep 14 11:08 AM | Frelick Jeff | Chief Executive Officer | Sep 11 '23 | Buy | 0.69 | 9,500 | 6,530 | 17,204 | Sep 12 11:34 AM | Walsh Deina H | Chief Financial Officer | Sep 06 '23 | Buy | 0.71 | 7,000 | 4,967 | 7,000 | Sep 07 10:45 AM | Frelick Jeff | Chief Executive Officer | Aug 31 '23 | Buy | 0.66 | 7,600 | 5,020 | 7,704 | Sep 05 05:05 PM |
|
|
|
|
Market Cap | 86.89M | EPS (ttm) | -2.69 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 39.15% |
Dividend | - | Sales Q/Q | - |
Insider Own | 72.32% | Inst Own | 22.64% |
Insider Trans | -0.46% | Inst Trans | -68.24% |
Short Float | 0.29% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.32M | 52W Range | 1.14 - 47.40 |
|
|
|
XBP Europe Holdings, Inc. is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation of businesses. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and services partner for its clients. The company is headquartered in Irving, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
CFAC Holdings VIII, LLC. | 10% Owner | Dec 14 '23 | Sale | 11.43 | 100,676 | 1,150,712 | 6,601,904 | Dec 18 05:58 PM |
|
|
|
|
Market Cap | 38.48M | EPS (ttm) | -0.00 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.88 | EPS Q/Q | -422.46% |
Dividend | - | Sales Q/Q | - |
Insider Own | 54.73% | Inst Own | 2.48% |
Insider Trans | 0.00% | Inst Trans | 5.83% |
Short Float | 0.11% | Earnings | May 14/a |
Analyst Recom | - | Target Price | - |
Avg Volume | 105.92K | 52W Range | 0.99 - 19.75 |
|
|
|
Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is headquartered in Jackson, WY. |
|
| |
|
Market Cap | 1.85B | EPS (ttm) | -3.18 |
P/E | - | EPS this Y | 101.17% |
Forward P/E | - | EPS next Y | -968.43% |
PEG | - | EPS past 5Y | 11.55% |
P/S | 1.86 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 69.08% |
Dividend | - | Sales Q/Q | 15.94% |
Insider Own | 4.98% | Inst Own | 57.32% |
Insider Trans | -0.67% | Inst Trans | 3.20% |
Short Float | 33.68% | Earnings | May 10/b |
Analyst Recom | 2.00 | Target Price | 18.00 |
Avg Volume | 12.77M | 52W Range | 3.53 - 15.00 |
|
|
|
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Dubovsky Filip | President, R&D | May 14 '24 | Option Exercise | 6.97 | 19,652 | 136,974 | 86,265 | May 15 09:15 PM | Dubovsky Filip | President, R&D | May 14 '24 | Sale | 13.90 | 47,312 | 657,637 | 38,953 | May 15 09:15 PM | O'Hara Elaine | EVP, Chief Strategy Officer | Mar 01 '24 | Option Exercise | 5.39 | 19,600 | 105,644 | 19,600 | Mar 05 07:30 PM | Dubovsky Filip | President, R&D | Dec 14 '23 | Option Exercise | 5.69 | 2,833 | 16,120 | 55,150 | Dec 18 05:00 PM | Dubovsky Filip | President, R&D | Nov 05 '23 | Option Exercise | 7.06 | 1,400 | 9,884 | 52,994 | Nov 07 05:30 PM |
|
|
|
|
Market Cap | - | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | - | Inst Own | - |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | May 09/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 500.29K | 52W Range | 0.81 - 8.37 |
|
|
|
| |
|
Market Cap | 70.62M | EPS (ttm) | -3.74 |
P/E | - | EPS this Y | -0.45% |
Forward P/E | - | EPS next Y | -1.84% |
PEG | - | EPS past 5Y | 39.98% |
P/S | - | EPS next 5Y | - |
P/B | 0.67 | EPS Q/Q | -21.41% |
Dividend | - | Sales Q/Q | - |
Insider Own | 19.88% | Inst Own | 39.29% |
Insider Trans | -4.26% | Inst Trans | -2.32% |
Short Float | 6.25% | Earnings | May 02/b |
Analyst Recom | 1.00 | Target Price | 27.80 |
Avg Volume | 361.65K | 52W Range | 1.04 - 5.24 |
|
|
|
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Opaleye Management Inc. | 10% Owner | May 10 '24 | Sale | 3.11 | 151,700 | 472,424 | 2,380,294 | May 10 06:57 PM | Opaleye Management Inc. | 10% Owner | May 09 '24 | Sale | 3.09 | 30,600 | 94,526 | 2,531,994 | May 10 06:57 PM |
|
|
|
|
Market Cap | 66.13M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 53.46% | Inst Own | - |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 7.07% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 8.00 |
Avg Volume | 5.02M | 52W Range | 2.08 - 29.50 |
|
|
|
Mobile-health Network Solutions operates as an investment holding company. The company through its subsidiaries provides telehealth solutions through MaNaDr platform. The platform seeks to offer users the ability to teleconsult with doctors and prescribed and delivered with the medication at their doorsteps. The company's segments include: Telemedicine and Other Services, and Sale of Medicine and Medical Devices. The Telemedicine and Other Services segment includes providing teleconsultation services to patients from both private and public sector. The Sale of Medicine and Medical Devices segment focuses on selling prescription drugs, non-prescription drugs, and healthcare products to clinics and end customers offline and online. The company was founded by Tung Yeng Siaw and Pui Pui Teoh on July 28, 2016 and is headquartered in Singapore. |
|
| |
|
Market Cap | 16.16M | EPS (ttm) | -1.77 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 9.63 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 18.25% | Inst Own | 0.36% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 6.84% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 468.31K | 52W Range | 4.20 - 1529.00 |
|
|
|
U Power Ltd. engages in the provision of vehicle sourcing. The firm broker sales of vehicles between automobile wholesalers and buyers, including small and medium sized vehicle dealers and individual customers. It also engages in the development of its proprietary battery-swapping technology which is designed to provide a comprehensive battery power solution for electric vehicles. The company was founded by Jia Li in 2013 and is headquartered in Shanghai, China. |
|
|
|
Market Cap | 1.20B | EPS (ttm) | -17.57 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 48.84% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 73.25% |
Dividend | - | Sales Q/Q | - |
Insider Own | 83.59% | Inst Own | 0.92% |
Insider Trans | -0.08% | Inst Trans | -1.38% |
Short Float | 0.54% | Earnings | May 09/a |
Analyst Recom | 2.00 | Target Price | 45.00 |
Avg Volume | 69.46K | 52W Range | 3.15 - 30.40 |
|
|
|
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
USMAN NASSIM | Director | May 01 '24 | Option Exercise | 6.93 | 20,000 | 138,600 | 21,636 | May 02 06:19 PM | USMAN NASSIM | Director | May 01 '24 | Sale | 14.13 | 20,000 | 282,577 | 1,636 | May 02 06:19 PM | USMAN NASSIM | Director | Apr 01 '24 | Option Exercise | 6.93 | 20,000 | 138,600 | 21,636 | Apr 03 04:01 PM | USMAN NASSIM | Director | Apr 01 '24 | Sale | 16.15 | 20,000 | 323,000 | 1,636 | Apr 03 04:01 PM | USMAN NASSIM | Director | Mar 15 '24 | Option Exercise | 6.93 | 20,000 | 138,600 | 21,636 | Mar 19 04:47 PM |
|
|
|
|
Market Cap | 192.40M | EPS (ttm) | -2.97 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 0.28 | EPS next 5Y | 21.90% |
P/B | 1.22 | EPS Q/Q | 421.48% |
Dividend | 2.33% | Sales Q/Q | -8.05% |
Insider Own | 12.82% | Inst Own | 59.82% |
Insider Trans | 0.00% | Inst Trans | -0.52% |
Short Float | 0.51% | Earnings | May 09/b |
Analyst Recom | 3.00 | Target Price | 17.00 |
Avg Volume | 143.23K | 52W Range | 3.98 - 7.89 |
|
|
|
Tredegar Corp. engages in the manufacture of polyethylene (PE) plastic films, polyester films, and aluminum extrusions. It operates through the following segments: PE Films, Flexible Packaging Films and Aluminum Extrusions. The PE Films segment manufactures plastic films, elastics, and laminate materials utilized in personal care materials, surface protection films and specialty and optical lighting applications. The Flexible Packaging Films segment produces polyester-based films for use in packaging applications. The Aluminum Extrusions segment provides soft-alloy and medium-strength aluminum extrusions for building and construction, automotive, consumer durables, machinery and equipment, electrical and distribution markets. The company was founded in 1988 and is headquartered in Richmond, VA. |
|
|